Notch1 Pathway Activation Results from the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides.

[1]  F. Climent,et al.  MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma. , 2015, The Journal of investigative dermatology.

[2]  R. Aguiar,et al.  A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B and T cell malignancies , 2014, Leukemia.

[3]  G. Ferrara,et al.  A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert‐Bazin type) mycosis fungoides , 2014, The British journal of dermatology.

[4]  R. Gniadecki,et al.  The importance of Notch signaling in peripheral T-cell lymphomas , 2014, Leukemia & lymphoma.

[5]  Ting-Ting Huang,et al.  Interplay between microRNAs and the STAT3 signaling pathway in human cancers. , 2013, Physiological genomics.

[6]  M. Esteller,et al.  miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells , 2013, PloS one.

[7]  Y. Mo,et al.  Notch-associated microRNAs in cancer. , 2013, Current drug targets.

[8]  Gerry Melino,et al.  Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation , 2013, Cell cycle.

[9]  Nicholas B. Levine,et al.  miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. , 2013, Cancer research.

[10]  R. Gniadecki,et al.  Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ‐secretase inhibitor I in cutaneous T‐cell lymphoma , 2013, The British journal of dermatology.

[11]  J. van Es,et al.  NOTCH1 signaling as a therapeutic target in Sézary syndrome. , 2012, The Journal of investigative dermatology.

[12]  S. Whittaker,et al.  Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma. , 2012, The Journal of investigative dermatology.

[13]  Robert Gniadecki,et al.  miR-122 Regulates p53/Akt Signalling and the Chemotherapy-Induced Apoptosis in Cutaneous T-Cell Lymphoma , 2012, PloS one.

[14]  David Haussler,et al.  Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma , 2011, Proceedings of the National Academy of Sciences.

[15]  L. van der Fits,et al.  miRNA expression profiling of mycosis fungoides , 2011, Molecular oncology.

[16]  M. Esteller,et al.  Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome , 2011, Epigenetics.

[17]  Simone Brabletz,et al.  The ZEB1/miR‐200 feedback loop controls Notch signalling in cancer cells , 2011, The EMBO journal.

[18]  Diana M Vallejo,et al.  Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells , 2011, The EMBO journal.

[19]  R. Gniadecki,et al.  Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma. , 2010, Blood.

[20]  R. Gniadecki,et al.  Notch signalling in primary cutaneous CD30+ lymphoproliferative disorders: a new therapeutic approach? , 2010, The British journal of dermatology.

[21]  A. Statnikov,et al.  The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. , 2010, Cancer cell.

[22]  B. Kaczkowski,et al.  Changes in oncomiR expression in CTCL cell lines during apoptosis induced by Notch inhibition. , 2010, Leukemia research.

[23]  Kwan Yeung Wong,et al.  Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies , 2010, PloS one.

[24]  V. Romagosa,et al.  Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. , 2010, The Journal of investigative dermatology.

[25]  Martha R. Stampfer,et al.  Role for DNA Methylation in the Regulation of miR-200c and miR-141 Expression in Normal and Cancer Cells , 2010, PloS one.

[26]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.

[27]  N. López-Bigas,et al.  Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer , 2009, Proceedings of the National Academy of Sciences.

[28]  R. Gniadecki,et al.  Potential involvement of Notch1 signalling in the pathogenesis of primary cutaneous CD30‐positive lymphoproliferative disorders , 2008, The British journal of dermatology.

[29]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[30]  B. Dörken,et al.  Notch signaling in leukemias and lymphomas. , 2008, Current molecular medicine.

[31]  M. Herlyn,et al.  Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. , 2005, The Journal of clinical investigation.

[32]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[33]  J. Aster,et al.  T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling , 2004, Current opinion in hematology.

[34]  K. Raj,et al.  The role of Notch in tumorigenesis: oncogene or tumour suppressor? , 2003, Nature Reviews Cancer.

[35]  W. Pear,et al.  Cutting edge: protective effects of notch-1 on TCR-induced apoptosis. , 1999, Journal of immunology.

[36]  J. Sklar,et al.  TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms , 1991, Cell.

[37]  F. Tacchini-Cottier,et al.  The role of Notch in the differentiation of CD4⁺ T helper cells. , 2012, Current topics in microbiology and immunology.

[38]  M. Esteller,et al.  Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. , 2004, Haematologica.